Amoneta Diagnostics attends the AD/PD™ 2024 International Conference

We are innovators in the pursuit of scientific progress and therapeutic advancements for neurodegenerative disorders.

Amoneta Diagnostics announces its participation in the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases in Lisbon. As innovators in the pursuit of scientific progress and therapeutic advancements for neurodegenerative disorders, we have had opportunity to engage with fellow experts and present our latest innovation: the APO-Easy® Genotyping Kit.

Designed to enhance Alzheimer’s disease (AD) diagnosis and patient management, the APO-Easy® Genotyping kit detects specific single nucleotide polymorphisms (SNPs) associated with the APOE gene. This genetic information is pivotal in assessing an individual’s susceptibility to AD, particularly concerning the ε4 allele, a well-established risk factor for late-onset AD.

Our commitment to precision medicine is underscored by the potential of the APO-Easy® Genotyping Kit to inform personalized treatment strategies, including the usage of emerging disease-modifying therapies such as monoclonal antibodies. As we navigate the CE-marking process, ensuring compliance with rigorous regulatory standards, we anticipate its imminent integration into clinical practice, offering clinicians invaluable insights for informed decision-making.

At AD/PD™ 2024, we have shared our expertise, exchanged insights, and forged collaborative partnerships to propel the field of neurodegenerative disease projects forward.